Managing Director
Alex Mayweg, Ph.D.
Background
Alexander Mayweg, Ph.D., is a Managing Director and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios, programs and teams within Roche Pharma Research and Early Development.
Since joining Versant in 2016, he has been involved in launching and investing in a number of Versant’s portfolio companies including Black Diamond (BDTX), Monte Rosa (GLUE), Bright Peak, Enterprise (acquired), T-knife and Matterhorn.
History
Prior to joining Versant, Alex served as global head of chemistry at Roche and over 14 years at the company has held a range of other scientific leadership positions. Prior to Roche, Alex earned a Ph.D. in organic chemistry at Oxford University, followed by post-doctorate training at Stanford University. His undergraduate degree was in chemistry from the Imperial College in London.